BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 11/02/22

BiondVax provides plan to address Nasdaq compliance PR Newswire JERUSALEM , Nov. 2, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing i...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, has announced that its Director of Investor Relations, Joshua Phillipson, will attend a...

Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesse...

BiondVax to present at LD Micro Investor Conference in Los Angeles PR Newswire JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and comme...

BiondVax Pharmaceuticals ( NASDAQ: BVXV ) said received a letter from Nasdaq for not being in compliance with the exchange's rule of minimum $2.5M in stockholders' equity for continued listing on the Nasdaq Capital Market, The company noted that the letter was based...

BiondVax announces financial plans to support its ongoing NanoAb pipeline development PR Newswire JERUSALEM , Israel , Sept. 30, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on dev...

BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19 PR Newswire JERUSALEM , Sept. 20, 2022 /PRNewswi...

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing, and c...

Biondvax Pharmaceuticals press release ( NASDAQ: BVXV ): Q2 GAAP EPS of -NIS0.02. As of June 30, 2022, BiondVax had cash and cash equivalents of NIS39.5M ($11.3 million) compared to NIS 54.0M as of December 31, 2021. For further details see: Bionvax Pharmaceutica...

BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update PR Newswire JERUSALEM , Aug. 25, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing in...